WO2005056571A1 - Improved synthesis of 2-substituted adenosines - Google Patents
Improved synthesis of 2-substituted adenosines Download PDFInfo
- Publication number
- WO2005056571A1 WO2005056571A1 PCT/GB2004/005090 GB2004005090W WO2005056571A1 WO 2005056571 A1 WO2005056571 A1 WO 2005056571A1 GB 2004005090 W GB2004005090 W GB 2004005090W WO 2005056571 A1 WO2005056571 A1 WO 2005056571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adenosine
- pentaacetate
- substituted
- pentabenzoyl
- nitro
- Prior art date
Links
- XNLWOLKCCPOLFA-UHFFFAOYSA-N CC(N(C(C)=O)c1nc([N+]([O-])=O)nc2c1nc[n]2C(C1OC(C)=O)OC(COC(C)=O)C1OC(C)=O)=O Chemical compound CC(N(C(C)=O)c1nc([N+]([O-])=O)nc2c1nc[n]2C(C1OC(C)=O)OC(COC(C)=O)C1OC(C)=O)=O XNLWOLKCCPOLFA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Definitions
- This invention relates to synthesis of 2-substituted adenosines, such as spongosine (2- methoxyadenosine) and to synthesis of intermediates for use in the synthesis of such compounds.
- Spongosine was considered an unusual nucleoside in that it was not only the first methoxypurine to be found in nature but also one of the first O- methyl compounds to be isolated from animal tissues.
- Spongosine was reported by Cook et al. (J. Org. Chem. 1980, 45, 4020) as a byproduct in the methylation reaction of isoguanosine by methyl iodide. Both the desired 1-methylisoguanosine and the spongosine were obtained in poor crude yields (19 and 30% respectively).
- the crude spongosine fragment was first purified by column chromatography on silica gel (eluent: chloroform/methanol) and then recrystallised from water to provide a sample which melted between 189-192°C (7% yield pure).
- the 2-nitroadenosine pentaacetate was produced by nitration of adenosine pentaacetate with tetrabutylammonium nitrate/trifluoroacetic anhydride (TBAN/TFAA), and (in Wanner et al.) the adenosine pentaacetate was formed by treatment of adenosine with acetic anhydride and DMAP: 2-nitroadenosine pentaacetate CN eOH
- a disadvantage of this method is that the spongosine is not produced in high yield or purity.
- a further disadvantage of the method is that it involves use of the toxic reagent potassium cyanide. It is desired, therefore, to provide alternative methods of synthesis of spongosine, and to improve the yield and purity of the spongosine produced.
- a method of synthesis of a 2-substituted adenosine of formula I which comprises converting 2-nitro pentabenzoyl adenosine to the 2-substituted adenosine:
- R C ⁇ _ alkoxy (straight or branched), a phenoxy group (unsubstituted, or mono-, or di-substituted by halo, amino, CF 3 -, cyano, nitro, C ⁇ _ ⁇ alkyl, or C g alkoxy), a benzyloxy group (unsubstituted, or mono-, or di-substituted by halo, amino, CF 3 -, cyano, nitro, C ⁇ -6 alkyl, or C 1-6 alkoxy), or a benzoyl group (unsubstituted, or mono-, or di-substituted by halo, amino, CF 3 -, cyano, nitro, C ⁇ g alkyl, or C g alkoxy).
- R methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy, benzyloxy, or benzoyl.
- 2-nitro- ⁇ entabenzoyl adenosine has increased organic solubility, stability and crystallinity compared to 2-nitroadenosine pentaacetate.
- the 2-nitro- pentabenzoyl adenosine is, therefore, easier to handle than 2-nitroadenosine pentaacetate, and can be made in higher yield and purity than this compound.
- the yield and purity of the spongosine produced is thereby also improved.
- Other 2- substituted adenosines can also be produced in high yield and purity using 2-nitro- pentabenzoyl adenosine as intermediate.
- the 2-nitro-pentabenzoyl adenosine is converted to the 2-substituted adenosine by reacting the 2-nitro-pentabenzoyl adenosine with a suitable anion (for example C 1-6 alkoxide anion, or a phenoxide anion), or by deprotecting the 2-nitro- pentabenzoyl adenosine and reaction with a suitable anion (for example C 1-6 alkoxide anion, or a phenoxide anion)
- a suitable anion for example C 1-6 alkoxide anion, or a phenoxide anion
- synthesise spongosine this may be achieved by reaction with potassium cyanide and methanol as detailed in Deghati et al, and Wanner et al.
- it is preferred that less toxic sources of the methoxide anion are used.
- Preferred sources are MeOH/NaOMe, MeOH/n-BuLi, MeOH
- 2-substituted adenosines of formula I may be made by treatment of 2-nitro- pentabenzoyl adenosine with sodium hydroxide, sodium hydride, butyl lithium, or KOTiu, and an appropriate alcohol (for example C 1-6 alcohol, or phenol).
- KO 4 Bu may be used with phenol.
- 2-nitro pentabenzoyl adenosine is also provided according to the invention.
- methods of the invention further comprise converting pentabenzoyl adenosine to 2-nitro-pentabenzoyl adenosine.
- a method of synthesising 2-nitro-pentabenzoyl adenosine or a 2-substituted adenosine of formula I which comprises converting pentabenzoyl adenosine to 2-nitro-pentabenzoyl adenosine.
- Conversion of pentabenzoyl adenosine to 2-nitro-pentabenzoyl adenosine may be achieved by nitrating pentabenzoyl adenosine with a suitable nitrating reagent, such as tetrabutylammonium nitrate (TBAN) or tetramethylammonium nitrate (TMAN).
- a suitable nitrating reagent such as tetrabutylammonium nitrate (TBAN) or tetramethylammonium nitrate (TMAN).
- TBAN tetrabutylammonium nitrate
- TMAN tetramethylammonium nitrate
- nitration is carried out using TBAN or TMAN with tri ⁇ uoroacetic anhydride (TBAN/TFAA, or TMAN/TFAA).
- TBAN/TFAA or TMAN/TFAA is in dichloromethane (DCM).
- 2-nitro-pentabenzoyl adenosine has increased organic solubility and crystallinity compared to 2-nitroadenosine pentaacetate.
- a particular advantage of these properties is that, in contrast to 2-nitroadenosine pentaacetate, much or all of the TBAN or TMAN can be removed from the 2-nitro-pentabenzoyl adenosine by aqueous work- up, preferably followed by recrystallisation.
- TMAN is used as nitrating agent rather than TBAN, since we have found that TMAN is easier to remove than TBAN.
- Preferably 3-5 washes are carried out in the aqueous work-up, and preferably 2 or 3 recrystallisations are carried out.
- aqueous work-up of the 2-nitro-pentabenzoyl adenosine produced may be carried out by dissolving the compound in an organic solvent (such as ethyl acetate or DCM), and washing the resulting solution with water.
- an organic solvent such as ethyl acetate or DCM
- washes In general, a minimum of three washes has been found to be required to remove a large proportion of the TBAN or TMAN. However, five washes are generally carried out to ensure as much TBAN or TMAN as possible is removed.
- Recrystallisation may be carried out by removing the organic solvent after the solution has been washed with water, dissolving the 2-nitro-pentabenzoyl adenosine in EtOAc/ethanol, or dichloromethane/ethanol, and crystallising the 2-nitro- pentabenzoyl adenosine from this solution.
- the increased organic solubility of the penta-benzoyl compounds compared with the penta-acetyl compounds ensures that only an insignificant amount of compound is lost by aqueous work-up and recrystallisation.
- methods of the invention further comprise converting adenosine to pentabenzoyl adenosine.
- a method of synthesising pentabenzoyl adenosine, 2-nitro-pentabenzoyl adenosine, or a 2-substituted adenosine of formula I which comprises converting adenosine to pentabenzoyl adenosine.
- Conversion of adenosine to pentabenzoyl adenosine may be achieved by benzoylating adenosine with a suitable benzoylating reagent, such as benzoyl chloride.
- a suitable base such as pyridine, should also be used.
- Ditnethylformamide (DMF) may be used as solvent, but preferably the adenosine is dissolved/suspended in pyridine as this gives cleaner results.
- pentabenzoyl adenosine An advantage of use of pentabenzoyl adenosine is that it can be more readily purified than adenosine pentaacetate.
- pentabenzoyl adenosine was purified by aqueous work-up followed by recrystallisation. This was preferable to purification of adenosine pentaacetate which involved column chromatography during which some decomposition and loss of product occurred.
- pentabenzoyl adenosine in the synthesis of 2-nitro pentabenzoyl adenosine, or a 2-substituted adenosine of formula I.
- Methods of the invention allow synthesis of products more easily, and with greater yield and purity than the known method of Deghati et al. and Wanner et al. which uses acetyl protecting groups. We have appreciated that this is due to the increased organic solubility, stability and crystallinity of the compounds used in the invention.
- a method of synthesising a 2-substituted adenosine of formula I which comprises: nitrating adenosine pentaacetate using TBAN or TMAN to produce 2-nitroadenosine pentaacetate; reducing the amount of TBAN or TMAN contaminating the 2- nitroadenosine pentaacetate; and then producing the 2-substituted adenosine from the 2-nitroadenosine pentaacetate:
- R C g alkoxy (straight or branched), a phenoxy group (unsubstituted, or mono-, or di-substituted by halo, amino, CF3-, cyano, nitro, C g alkyl, or C ⁇ g alkoxy), a benzyloxy group (unsubstituted, or mono-, or di-substituted by halo, amino, CF 3 -, cyano, nitro, C ⁇ -6 alkyl, or C 1-6 alkoxy), or a benzoyl group (unsubstituted, or mono-, or di-substituted by halo, amino, CF 3 -, cyano, nitro, C g alkyl, or C ⁇ g alkoxy).
- R is methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, phenoxy, benzyloxy, or benzoyl.
- a method of reducing the amount of TBAN or TMAN contaminating 2-nitroadenosine pentaacetate formed by nitration of adenosine pentaacetate with TBAN or TMAN which comprises triturating the 2- nitroadenosine pentaacetate with isopropanol and washing the triturated 2- nitroadenosine pentaacetate with water to reduce the amount of TBAN or TMAN.
- nitration is carried out using TBAN or TMAN with trifluoroacetic anhydride (TBAN/TFAA, or TMAN/TFAA).
- TBAN/TFAA trifluoroacetic anhydride
- TMAN/TFAA trifluoroacetic anhydride
- the TBAN/TFAA or TMAN/TFAA is in dichloromethane (DCM).
- DCM dichloromethane
- 2-nitroadenosine pentaacetate may be converted to the 2-substituted adenosine by deprotecting the 2-nitroadenosine pentaacetate and reaction with a suitable anion (for example a C 1-6 alkoxide anion, or a phenoxide anion).
- a suitable anion for example a C 1-6 alkoxide anion, or a phenoxide anion.
- To synthesise spongosine this this may be achieved by reaction with potassium cyanide and methanol as detailed in Deghati et al, and Wanner et al.
- it is preferred that less toxic sources of the methoxide anion are used.
- Preferred sources are MeOH/NaOMe, MeOH/n-BuLi, MeOH/NaOH, MeOH/NaH, or MeOH/KO ⁇ u.
- a method of synthesising spongosine which comprises treating 2-nitroadenosine pentaacetate with MeOH/NaOMe, MeOH/n-BuLi, MeOH/NaOH or MeOH/NaH to form spongosine.
- Methods of the invention may further comprise converting adenosine to adenosine pentaacetate. This may be achieved by the method detailed by Deghati et al, and Wanner et al. However, we have appreciated that adenosine pentaacetate is produced only in low yield and purity using this method, and that the tetra-acetylated precursor is present as a major by-product.
- methods of the invention further comprise acylating adenosine to form an O-tri-acetyl and/or tetra-acetyl derivative of adenosine, isolating the derivative(s), and acylating the isolated derivative(s) to produce the adenosine pentaacetate intermediate.
- a method of synthesising adenosine pentaacetate, 2-nitroadenosine pentaacetate, or a 2-substituted adenosine of formula I which includes the following steps: acylating adenosine to form an O-tri-acetyl and/or tetra-acetyl derivative of adenosine, isolating the derivative(s), and acylating the isolated derivative(s) to produce adenosine pentaacetate.
- the O-tri-acetyl and/or tetra-acetyl derivative can be isolated using column chromatography.
- the adenosine may then be nitrated to form 2-nitroadenosine pentaacetate.
- the 2- nitroadenosine pentaacetate may then be converted to a 2-substituted adenosine of formula I, for example using a method of the invention.
- the yield and purity of the 2-substituted adenosine product may be improved if methods of the invention alternatively or additionally further comprise washing the adenosine pentaacetate intermediate to reduce the amount of contaminating adenosine tetraacetate before nitrating the washed adenosine pentaacetate.
- a method of synthesising adenosine pentaacetate, 2-nitroadenosine pentaacetate, or a 2-substituted adenosine of formula I which includes the following steps: acylating adenosine or an acylated derivative of adenosine to form adenosine pentaacetate; and washing the adenosine pentaacetate to reduce the amount of contaminating adenosine tetraacetate.
- adenosine pentaacetate To wash the adenosine pentaacetate, it is preferably dissolved in chloroform and washed with acetic acid solution (preferably 1M).
- the adenosine pentaacetate may then be nitrated to form 2-nitroadenosine pentaacetate.
- the 2-nitroadenosine pentaacetate may then be converted to a 2- substituted adenosine of formula I, for example using a method of the invention. It is thought that 2-nitroadenosine pentaacetate may be toxic. Thus, it may be desirable to ensure that a 2-substituted adenosine produced from 2-nitroadenosine pentaacetate is contaminated with as little 2-nitroadenosine pentaacetate as possible.
- this may be achieved by converting the 2-nitroadenosine pentaacetate to 2-chloroadenosine pentaacetate before converting the 2- chloroadenosine pentaacetate to the 2-substituted adenosine.
- conversion of 2-nitroadenosine pentaacetate to 2-chloroadenosine pentaacetate may be achieved by chlorinating the 2-nitroadenosine pentaacetate with a suitable chlorinating reagent, such as ammonium chloride.
- a method of synthesis of a 2-substituted adenosine of formula I which comprises converting 2- chloroadenosine pentaacetate to the 2-substituted adenosine.
- 2-chloroadenosine pentaacetate may be converted to the 2- substituted adenosine by deprotecting the 2-chloroadenosine pentaacetate and reaction with a suitable anion (for example a C 1-6 alkoxide anion, or a phenoxide anion).
- a suitable anion for example a C 1-6 alkoxide anion, or a phenoxide anion.
- a suitable anion for example a C 1-6 alkoxide anion, or a phenoxide anion.
- a 2-substituted adenosine of formula I or an intermediate for use in synthesis of a 2-substituted adenosine of formula I, produced by a method of the invention.
- Methods of the invention can be used to synthesise 2-substituted adenosines in high yield and purity. For example, we have been able to synthesise spongosine which is >96% pure.
- citric acid solution or 0.2 HCL could preferably be used.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04805918A EP1694691A1 (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosines |
AU2004296242A AU2004296242A1 (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosines |
US10/581,545 US20090131651A1 (en) | 2003-12-05 | 2004-12-03 | Synthesis of 2-substituted adenosines |
CA002552583A CA2552583A1 (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosines |
JP2006542018A JP2007513134A (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosine |
NZ546782A NZ546782A (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosines such as spongosine |
NO20063109A NO20063109L (en) | 2003-12-05 | 2006-07-04 | Improved synthesis of 2-substituted adenosines |
HK07102955.2A HK1095834A1 (en) | 2003-12-05 | 2007-03-20 | Improved synthesis of 2-substituted adenosines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0328321A GB0328321D0 (en) | 2003-12-05 | 2003-12-05 | Synthesis of 2-substituted adenosines |
GB0328319.9 | 2003-12-05 | ||
GB0328321.5 | 2003-12-05 | ||
GB0328319A GB0328319D0 (en) | 2003-12-05 | 2003-12-05 | Improved synthesis of 2-substituted adenosines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005056571A1 true WO2005056571A1 (en) | 2005-06-23 |
Family
ID=34680435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/005090 WO2005056571A1 (en) | 2003-12-05 | 2004-12-03 | Improved synthesis of 2-substituted adenosines |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090131651A1 (en) |
EP (1) | EP1694691A1 (en) |
JP (1) | JP2007513134A (en) |
KR (1) | KR20060125830A (en) |
AU (1) | AU2004296242A1 (en) |
CA (1) | CA2552583A1 (en) |
HK (1) | HK1095834A1 (en) |
NZ (1) | NZ546782A (en) |
WO (1) | WO2005056571A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103342727A (en) * | 2013-07-01 | 2013-10-09 | 淮海工学院 | Synthetic method of 2-methoxyl adenosine |
US11298432B2 (en) | 2008-01-03 | 2022-04-12 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Method for preparing a marked purine derivative, said derivative and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007526291A (en) * | 2004-03-05 | 2007-09-13 | ケンブリッジ・バイオテクノロジー・リミテッド | Adenosine receptor agonist |
AU2006331673B2 (en) | 2005-12-23 | 2013-02-28 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5384972A (en) * | 1976-12-29 | 1978-07-26 | Ajinomoto Co Inc | Nucleocide derivative |
US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
-
2004
- 2004-12-03 JP JP2006542018A patent/JP2007513134A/en active Pending
- 2004-12-03 NZ NZ546782A patent/NZ546782A/en unknown
- 2004-12-03 CA CA002552583A patent/CA2552583A1/en not_active Abandoned
- 2004-12-03 EP EP04805918A patent/EP1694691A1/en not_active Withdrawn
- 2004-12-03 WO PCT/GB2004/005090 patent/WO2005056571A1/en active Application Filing
- 2004-12-03 US US10/581,545 patent/US20090131651A1/en not_active Abandoned
- 2004-12-03 KR KR1020067013388A patent/KR20060125830A/en not_active Application Discontinuation
- 2004-12-03 AU AU2004296242A patent/AU2004296242A1/en not_active Abandoned
-
2007
- 2007-03-20 HK HK07102955.2A patent/HK1095834A1/en not_active IP Right Cessation
Non-Patent Citations (4)
Title |
---|
BARTLETT R T ET AL: "Synthesis and pharmacological evaluation of a series of analogues of 1-methylisoguanosine", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 24, 1981, pages 947 - 954, XP002225573, ISSN: 0022-2623 * |
BERGMANN W ET AL: "CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS. XLIII. THE NUCLEOSIDES OF SPONGES. V. THE SYNTHESIS OF SPONGOSINE", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 22, December 1957 (1957-12-01), pages 1575 - 1577, XP001205635, ISSN: 0022-3263 * |
DEGHATI P Y F ET AL: "Regioselective nitration of purine nucleosides: synthesis of 2-nitroadenosine and 2-nitroinosine", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 8, February 2000 (2000-02-01), pages 1291 - 1295, XP004188609, ISSN: 0040-4039 * |
WANNER M J ET AL: "2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 18, September 2000 (2000-09-01), pages 2141 - 2144, XP004208330, ISSN: 0960-894X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298432B2 (en) | 2008-01-03 | 2022-04-12 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Method for preparing a marked purine derivative, said derivative and uses thereof |
CN103342727A (en) * | 2013-07-01 | 2013-10-09 | 淮海工学院 | Synthetic method of 2-methoxyl adenosine |
Also Published As
Publication number | Publication date |
---|---|
HK1095834A1 (en) | 2007-05-18 |
KR20060125830A (en) | 2006-12-06 |
AU2004296242A1 (en) | 2005-06-23 |
US20090131651A1 (en) | 2009-05-21 |
CA2552583A1 (en) | 2005-06-23 |
JP2007513134A (en) | 2007-05-24 |
NZ546782A (en) | 2010-04-30 |
EP1694691A1 (en) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5672698A (en) | Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine | |
JP3042073B2 (en) | Nucleoside derivative and method for producing the same | |
EP1694691A1 (en) | Improved synthesis of 2-substituted adenosines | |
JP2004538317A (en) | Method for preparing L-ribavirin | |
KR100699099B1 (en) | 1-?-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof | |
EP0427587B1 (en) | Process for the preparation of AZT (3'-azido-3'-deoxy-thymidine) and related compounds | |
US5608049A (en) | Preparation of d4T from 5-methyluridine | |
WO2005054269A1 (en) | Improved synthesis of 2-substituted adenosines | |
WO2004069851A1 (en) | Process for the preparation of ribofuranose derivatives | |
CA2226363C (en) | D-pentofuranose derivatives and process for preparing the same | |
EP1699805A1 (en) | Process for the preparation of 1-chloro-3,5-di-o-acyl-2-deoxy-l-ribofuranoside derivatives | |
JP2547125B2 (en) | 2 ', 3'-dideoxy-2', 3'-disubstituted-nucleosides and process for their production | |
JP2007137843A (en) | Method for producing ribofuranose compound and purine nucleoside compound | |
JPH0154359B2 (en) | ||
WO1997006179A1 (en) | Process for producing azido nucleoside derivatives | |
JPH0153678B2 (en) | ||
JPH09110893A (en) | Production of 3'-amino-3'-deoxynucleoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480035597.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004296242 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546782 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2552583 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004296242 Country of ref document: AU Date of ref document: 20041203 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004296242 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006542018 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004805918 Country of ref document: EP Ref document number: 1020067013388 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2462/CHENP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004805918 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067013388 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581545 Country of ref document: US |